aminolevulinic acid has been researched along with Impaired Glucose Tolerance in 3 studies
Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recently, sarcopenia has attracted attention as therapeutic target because it constitutes a risk factor for metabolic and cardiovascular diseases." | 5.46 | Treatment of sarcopenia and glucose intolerance through mitochondrial activation by 5-aminolevulinic acid. ( Endo, S; Fujii, C; Fujii, K; Hagiwara, A; Inoue, H; Itoh, H; Kawai, T; Mitsuishi, M; Miyashita, K; Muraki, A; Nakajima, M; Ryuzaki, M; Sato, M; Tamaki, M; Tanaka, T; Uto, A, 2017) |
| "Recently, sarcopenia has attracted attention as therapeutic target because it constitutes a risk factor for metabolic and cardiovascular diseases." | 1.46 | Treatment of sarcopenia and glucose intolerance through mitochondrial activation by 5-aminolevulinic acid. ( Endo, S; Fujii, C; Fujii, K; Hagiwara, A; Inoue, H; Itoh, H; Kawai, T; Mitsuishi, M; Miyashita, K; Muraki, A; Nakajima, M; Ryuzaki, M; Sato, M; Tamaki, M; Tanaka, T; Uto, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, C | 1 |
| Miyashita, K | 1 |
| Mitsuishi, M | 1 |
| Sato, M | 1 |
| Fujii, K | 1 |
| Inoue, H | 1 |
| Hagiwara, A | 1 |
| Endo, S | 1 |
| Uto, A | 1 |
| Ryuzaki, M | 1 |
| Nakajima, M | 2 |
| Tanaka, T | 2 |
| Tamaki, M | 1 |
| Muraki, A | 1 |
| Kawai, T | 1 |
| Itoh, H | 1 |
| Nakamura, Y | 1 |
| Haraguchi, A | 1 |
| Shigeno, R | 1 |
| Ito, A | 1 |
| Horie, I | 1 |
| Kawakami, A | 1 |
| Abiru, N | 1 |
| Saitoh, S | 1 |
| Okano, S | 1 |
| Nohara, H | 1 |
| Nakano, H | 1 |
| Shirasawa, N | 1 |
| Naito, A | 1 |
| Yamamoto, M | 1 |
| Kelly, VP | 1 |
| Takahashi, K | 1 |
| Nakajima, O | 1 |
1 trial available for aminolevulinic acid and Impaired Glucose Tolerance
| Article | Year |
|---|---|
A single-arm, open-label, intervention study to investigate the improvement of glucose tolerance after administration of the 5-aminolevulinic acid (5-ALA) in the patients with mitochondrial diabetes mellitus.
Topics: Adenosine Triphosphate; Adult; Aminolevulinic Acid; Blood Glucose; Citric Acid; Deafness; Diabetes M | 2021 |
2 other studies available for aminolevulinic acid and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Treatment of sarcopenia and glucose intolerance through mitochondrial activation by 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Electron Transport | 2017 |
5-aminolevulinic acid (ALA) deficiency causes impaired glucose tolerance and insulin resistance coincident with an attenuation of mitochondrial function in aged mice.
Topics: 5-Aminolevulinate Synthetase; Aminolevulinic Acid; Animals; Blood Glucose; Glucagon; Gluconeogenesis | 2018 |